Physician profile
Kylie Plummer
NPI 1669709747
$10,850.43
in general payments reported to CMS, 2019-2025
27 companies · $2,897 in 2025
The $2,897 reported for 2025 was more than what 95% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,118 · 2022: $1,440 · 2023: $2,550 · 2024: $2,846 · 2025: $2,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,098 · Education: $195.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,097.87 |
| Education | $195.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,177.32 | 2021-2025 | |
| Janssen Biotech, INC. | $1,891.78 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $795.98 | 2021-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $743.26 | 2021-2025 | |
| Amgen INC. | $663.27 | 2021-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $603.83 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $547.77 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $459.15 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Leo Pharma INC. | $448.65 | 2021-2025 | Adbry, Spevigo |
| Regeneron Healthcare Solutions, INC. | $443.72 | 2021-2025 | Dupixent |
| Lilly USA, LLC | $361.75 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Dermavant Sciences, INC. | $254.71 | 2023-2024 | Vtama |
| Incyte Corporation | $213.72 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $205.24 | 2025 | Nemluvio, Aklief |
| Genentech USA, INC. | $179.66 | 2021-2025 | Xolair |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $169.18 | 2021-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $152.72 | 2023-2025 | Zoryve |
| Pfizer INC. | $135.67 | 2021-2023 | |
| Mayne Pharma Commercial LLC | $108.17 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Organon LLC | $69.75 | 2025 | Vtama |
| Acelrx Pharmaceuticals, INC. | $33.61 | 2021 | |
| Verrica Pharmaceuticals INC. | $28.45 | 2024 | Ycanth |
| Kowa Pharmaceuticals America, INC. | $26.77 | 2023 | Seglentis |
| Kyowa Kirin, INC. | $22.28 | 2024 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.03 | 2024 | Arazlo |
| Helsinn Therapeutics (U.S.), INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kylie Plummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.